All In Biotech

Drug Trial Radar · NCT06433505

A Study to Evaluate the Drug Levels, Metabolism and Excretion, and Absolute Bioavailability of BMS-986365 in Healthy Male Participants

A Phase 1, Open-label, Two-Part Study to Evaluate the Pharmacokinetics, Metabolism and Excretion, and Absolute Bioavailability of BMS-986365 in Healthy Male Participants

Last checked: Nov 19, 2026Latest source record: Mar 26, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

24

Actual

Start

May 30, 2024

Primary completion

Feb 14, 2025

Study completion Feb 28, 2025

Sponsor

Lead sponsor
CelgeneBristol Myers Squibb (BMY)
Sponsor type
Industry
First posted
May 29, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Non randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
Male only, from 18 years, up to 60 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The objective of this study is to assess the pharmacokinetics (PK) and absolute bioavailability of BMS-986365 and to investigate the PK, metabolite profile, routes and extent of elimination, and mass balance of BMS-986365.

Conditions

  • Healthy Volunteers

Interventions

  • BMS-986365Drug

    Specified dose on specified days

  • [14C] BMS-986365Drug

    Specified dose on specified days.

  • [14C] BMS-986409 + BMS-986410Drug

    Specified dose on specified days

  • [14C] BMS-986410 + BMS-986409Drug

    Specified dose on specified days

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Maximum observed concentration (Cmax)Time frame: Up to Day 60
  2. Time of maximum observed concentration (Tmax)Time frame: Up to Day 60
  3. Area under the plasma concentration-time curve from time zero to time of last quantifiable concentration (AUC(0-T))Time frame: Up to Day 60
  4. Area under the plasma concentration-time curve from time zero extrapolated to infinite time (AUC (INF))Time frame: Up to Day 60
  5. Apparent terminal plasma half-life (T-HALF)Time frame: Up to Day 60
  6. Total body clearance (CLT)Time frame: Up to Day 15
  7. Apparent total body clearance (CLT/F)Time frame: Up to Day 60
  8. Mean residence time (MRT)Time frame: Up to Day 15
  9. Apparent volume of distribution (Vz)Time frame: Up to Day 15
  10. Apparent volume of distribution (Vz/F)Time frame: Up to Day 60
  11. Absolute bioavailability (F)Time frame: Up to Day 15

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Local Institution - 0001

    Madison, Wisconsin

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.